Birdwatch Note
2024-11-24 12:19:33 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
イベルメクチンは日本の2つのランダム化比較試験(RCT)でも https://www.kowa.co.jp/news/2022/press20220926.html https://www.kitasato-u.ac.jp/khp/topics/2022/20220930.html 世界のRCTのメタ解析でも臨床アウトカムの改善への有効性は見だせていません https://academic.oup.com/cid/article/74/6/1022/6310839?login=false https://www.sciencedirect.com/science/article/pii/S0924857924001663?casa_token=BShl-qSiS2EAAAAA:lUaSQL960ThyZdOKwn5PXDJTZs6a3fQy_rFZ-vBBLIBKnjXOjZ-4Tve4AD5lkpkz5BslvBge0z8 ヒドロキシクロロキンも同様で、治療に関する使用に関してはRCTのメタで効果は検出できませんでした https://www.mdpi.com/2227-9059/12/10/2206 コルヒチンも同様でRCTのメタで有意差を残せていません https://bmjopen.bmj.com/content/14/4/e074373.abstract これはRCTで有効性を見だし早々と承認され https://dm-rg.net/news/2020/07/020449.html その後のメタでも有効性が確認された安価なデキサメタゾン↓等と対照的で、安価だから承認されなかったのではなく単純に臨床試験で再現性をもって結果を残せなかったため承認されていない事に注意が必要です https://www.tandfonline.com/doi/full/10.1080/17476348.2023.2177155#abstract
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1860597337292427414
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1860659519170421008
- noteId - 1860659519170421008
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1732450773409
- tweetId - 1860597337292427414
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- イベルメクチンは日本の2つのランダム化比較試験(RCT)でも https://www.kowa.co.jp/news/2022/press20220926.html https://www.kitasato-u.ac.jp/khp/topics/2022/20220930.html 世界のRCTのメタ解析でも臨床アウトカムの改善への有効性は見だせていません https://academic.oup.com/cid/article/74/6/1022/6310839?login=false https://www.sciencedirect.com/science/article/pii/S0924857924001663?casa_token=BShl-qSiS2EAAAAA:lUaSQL960ThyZdOKwn5PXDJTZs6a3fQy_rFZ-vBBLIBKnjXOjZ-4Tve4AD5lkpkz5BslvBge0z8 ヒドロキシクロロキンも同様で、治療に関する使用に関してはRCTのメタで効果は検出できませんでした https://www.mdpi.com/2227-9059/12/10/2206 コルヒチンも同様でRCTのメタで有意差を残せていません https://bmjopen.bmj.com/content/14/4/e074373.abstract これはRCTで有効性を見だし早々と承認され https://dm-rg.net/news/2020/07/020449.html その後のメタでも有効性が確認された安価なデキサメタゾン↓等と対照的で、安価だから承認されなかったのではなく単純に臨床試験で再現性をもって結果を残せなかったため承認されていない事に注意が必要です https://www.tandfonline.com/doi/full/10.1080/17476348.2023.2177155#abstract
Note Ratings
| rated at | rated by | |
| 2024-11-26 19:17:06 -0600 | Rating Details | |
| 2024-11-25 20:00:45 -0600 | Rating Details | |
| 2024-11-25 14:25:30 -0600 | Rating Details | |
| 2024-11-25 02:37:48 -0600 | Rating Details | |
| 2024-11-24 22:22:16 -0600 | Rating Details | |
| 2024-11-24 18:49:21 -0600 | Rating Details | |
| 2024-11-24 10:53:02 -0600 | Rating Details | |
| 2024-11-24 08:49:52 -0600 | Rating Details | |
| 2024-11-24 08:21:14 -0600 | Rating Details | |
| 2024-11-24 08:11:01 -0600 | Rating Details | |
| 2024-11-24 08:05:53 -0600 | Rating Details | |
| 2024-11-24 07:52:29 -0600 | Rating Details | |
| 2024-11-24 07:50:09 -0600 | Rating Details | |
| 2024-11-24 07:33:42 -0600 | Rating Details | |
| 2024-11-24 07:16:49 -0600 | Rating Details | |
| 2024-11-24 07:15:56 -0600 | Rating Details | |
| 2024-11-24 07:14:12 -0600 | Rating Details | |
| 2024-11-24 07:13:42 -0600 | Rating Details | |
| 2024-11-24 07:12:02 -0600 | Rating Details | |
| 2024-11-24 07:10:25 -0600 | Rating Details | |
| 2024-11-24 06:55:58 -0600 | Rating Details | |
| 2024-11-24 06:55:23 -0600 | Rating Details | |
| 2024-11-24 06:54:18 -0600 | Rating Details | |
| 2024-11-24 06:51:22 -0600 | Rating Details | |
| 2024-11-24 06:40:08 -0600 | Rating Details | |
| 2024-11-25 00:28:36 -0600 | Rating Details | |
| 2024-11-24 19:51:32 -0600 | Rating Details | |
| 2024-11-24 17:36:19 -0600 | Rating Details | |
| 2024-11-24 10:43:30 -0600 | Rating Details | |
| 2024-11-24 08:35:45 -0600 | Rating Details | |
| 2024-11-24 07:45:52 -0600 | Rating Details | |
| 2024-11-24 07:43:58 -0600 | Rating Details | |
| 2024-11-24 07:20:50 -0600 | Rating Details | |
| 2024-11-25 18:04:02 -0600 | Rating Details | |
| 2024-11-24 17:50:58 -0600 | Rating Details | |
| 2024-11-24 17:27:46 -0600 | Rating Details | |
| 2024-11-24 12:45:18 -0600 | Rating Details | |
| 2024-11-24 11:33:30 -0600 | Rating Details | |
| 2024-11-24 08:22:23 -0600 | Rating Details | |
| 2024-11-24 07:43:49 -0600 | Rating Details | |
| 2024-11-24 07:18:11 -0600 | Rating Details | |
| 2024-11-24 07:15:30 -0600 | Rating Details | |
| 2024-11-24 07:14:25 -0600 | Rating Details | |
| 2024-11-24 07:02:11 -0600 | Rating Details | |
| 2024-11-24 06:54:14 -0600 | Rating Details | |
| 2024-11-24 06:38:10 -0600 | Rating Details | |
| 2024-11-25 07:02:55 -0600 | Rating Details | |
| 2024-11-24 22:33:35 -0600 | Rating Details | |
| 2024-11-24 15:25:00 -0600 | Rating Details | |
| 2024-11-24 15:23:42 -0600 | Rating Details | |
| 2024-11-24 08:58:29 -0600 | Rating Details | |
| 2024-11-24 08:29:06 -0600 | Rating Details | |
| 2024-11-24 07:11:26 -0600 | Rating Details | |
| 2024-11-24 07:09:23 -0600 | Rating Details | |
| 2024-11-24 07:08:20 -0600 | Rating Details |